Leuphasyl
- Category
- Skin & Cosmetic
- Administration routes
- Topical
- Regulatory status
- Cosmetic ingredient
What it is
A synthetic pentapeptide applied topically, marketed as a needle-free complement to Botox that eases facial muscle contractions to soften expression lines. Human evidence is limited: a small uncontrolled 20-person study reported wrinkle improvement, and combination-formulation studies cannot isolate the peptide's effect. Safety data is limited, though risks so far seem mild. It is a cosmetic ingredient, not an FDA-approved drug.
Read Full recordStudied uses & evidence
Studied uses(5)
Reduction in expression wrinkle depth (manufacturer claims up to 47% combined with Argireline)
SpeculativeManufacturer's 47% figure is unpublished in-house data, not a peer-reviewed clinical trial.
Modulation of neurotransmitter release to reduce muscle micro-contractions
SpeculativeProposed mechanism relies on general enkephalin pharmacology, not tested directly on skin or muscle.
Synergistic anti-wrinkle effect when combined with Argireline (Hexapeptide-8)
SpeculativeNo published combination study, synergy claim rests on mechanism reasoning and manufacturer material.
Evidence limits
- Evidence Level
- Limited Evidence (Cosmetic Industry Data, Minimal Independent Clinical Trials)
The clinical evidence for Leuphasyl consists primarily of proprietary manufacturer studies from Lipotec and cosmetic formulation research. Independent peer-reviewed clinical trials are minimal. A 2026 computational study (PMID 41722287) provided academic validation of its molecular interactions with anti-aging targets, but this was in-silico/in-vitro only. The peptide is widely used in the cosmetics industry based on mechanistic plausibility and manufacturer efficacy claims rather than rigorous clinical trials.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(2)
Risks = level of concern: High · Moderate · Low · Theoretical
Skin irritation or allergic reaction (rare)
LowLimited independent safety data
Moderate
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.